Press ReleaseVALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking Dec 4, 2025 READ MORE
Press ReleaseVALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE Dec 4, 2025 READ MORE
Press ReleaseCardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA Oct 30, 2025 READ MORE
Press ReleaseCardiawave Strengthens Leadership with Appointment of Jonathan Freeman as Board Chairman Oct 23, 2025 READ MORE
Press ReleaseCardiawave annonce les résultats positifs à 12 mois de ses études “Valvosoft® FIM Study” et « Valvosoft® Pivotal Study » à l’EuroPCR! May 23, 2025 READ MORE
Press ReleaseCardiawave Announces Positive 12-Month Results from Its “Valvosoft® FIM Study” and “Valvosoft® Pivotal Study”, presented at EuroPCR! May 23, 2025 READ MORE
Press ReleaseCardiawave announces positive 6-month data from its Valvosoft Pivotal Study, presented at TCT Conference ! Oct 29, 2024 READ MORE
Press ReleaseCardiawave appoints Olivier Pierron as its Chief Executive Officer Apr 16, 2024 READ MORE
Press ReleaseCardiawave annonce la nomination d’Olivier Pierron en tant que Directeur Général Apr 16, 2024 READ MORE
Press ReleaseCardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis at the 73rd Annual Conference of the ACC – April 6–8, 2024, Atlanta (GA) Apr 5, 2024 READ MORE
